D 064/D 701 - Chong Kun Dang Pharmaceutical
Alternative Names: D-064/D-701 - Chong Kun Dang Pharmaceutical; D-701/D-064 - Chong Kun Dang PharmaceuticalLatest Information Update: 20 Jun 2024
At a glance
- Originator Chong Kun Dang
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Essential hypertension
Most Recent Events
- 13 May 2024 Chong Kun Dang Pharmaceutical completes phase-III trial for Essential hypertension in South Korea (NCT05931224)
- 26 Mar 2024 Chong Kun Dang Pharmaceutical completes a phase III trial in Essential hypertension in South Korea (NCT06121518)
- 31 Jul 2023 Chong Kun Dang Pharmaceutical initiates phase III trial for Essential hypertension in South Korea (NCT06121518)